Back to GOLDMAN SACHS GROUP INC GOLDMAN SACHS GROUP INC

QNCXQNCX
6 quarters

Position history for GOLDMAN SACHS GROUP INCGOLDMAN SACHS GROUP INC's holdings in QUINCE THERAPEUTICS INC

As of its Q1 2026 13F, Goldman Sachs held 16,064 shares of QNCX (Quince Therapeutics), worth $1,629. Goldman Sachs' 13F filings listed QNCX from Q4 2025 to Q1 2026, 2 quarterly filings.

Final Value

$0

Final Shares

0

Total Value Change

-$196,000

Total Shares Change

-88,354

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$18.19
0
2026-Q1
Decreased
16,064
-93.0%
$1,6290.0%$20.20
0
2025-Q4
New
229,695
-
$769,4780.0%$670.00
34
2022-Q4
Exited
0
-100.0%
$00.0%$127.40
0
2022-Q3
Decreased
29,598
-66.5%
$39,0000.0%$266.00
0
2022-Q2
First report
88,354
-
$196,0000.0%$444.00
0

Other major holders of QNCX: Capital World Investors, Capital International Investors, Capital Research Global Investors

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used